Yuki Mika, Komazawa Yoshinori, Kobayashi Yoshiya, Kusunoki Maho, Takahashi Yoshiko, Nakashima Sayaka, Uno Goichi, Ikuma Isao, Shizuku Toshihiro, Kinoshita Yoshikazu
Department of Internal Medicine, Izumo City General Medical Center, Izumo, Shimane, Japan.
Second Department of Internal Medicine, Shimane University, School of Medicine, Izumo, Shimane, Japan.
Curr Ther Res Clin Exp. 2015 May 4;77:58-62. doi: 10.1016/j.curtheres.2015.04.002. eCollection 2015 Dec.
Daikenchuto (DKT), a traditional Japanese herbal medicine, is widely used for treatment of gastrointestinal disorders. We evaluated the efficacy and safety of DKT for abdominal bloating in patients with chronic constipation.
To evaluate the efficacy and safety of DKT for the treatment of abdominal bloating.
After discontinuing as-needed use of laxatives, 10 patients received oral DKT for 14 days (15 g/d). To evaluate small intestinal bacteria overgrowth (SIBO), a glucose breath test was performed before and after treatment with DKT. Before beginning the treatment, 4 patients (40%) had a diagnosis of SIBO based on a positive glucose breath test result. In both the SIBO and non-SIBO groups, bowel movement frequency and stool form remained unchanged after DKT treatment.
For all patients, median total Gastrointestinal Symptoms Rating Scale score and the median Gastrointestinal Symptoms Rating Scale indigestion and constipation subscales were significantly decreased, whereas the median visual analog score for decreased abdominal bloating was significantly increased. Improvements of those symptoms were the same in both the SIBO and non-SIBO groups, indicating that DKT does not have effects on small intestine bacteria. No serious side effects were reported.
DKT treatment improved quality of life for patients with chronic constipation regardless of the presence of SIBO and showed no effects on small intestine bacteria. UMIN Clinical Trial Registry identifier: UMIN000008070.
大建中汤(DKT)是一种传统的日本草药,广泛用于治疗胃肠道疾病。我们评估了DKT治疗慢性便秘患者腹胀的疗效和安全性。
评估DKT治疗腹胀的疗效和安全性。
在按需停用泻药后,10例患者口服DKT,持续14天(15克/天)。为了评估小肠细菌过度生长(SIBO),在DKT治疗前后进行了葡萄糖呼气试验。在开始治疗前,4例患者(40%)基于葡萄糖呼气试验阳性被诊断为SIBO。在SIBO组和非SIBO组中,DKT治疗后排便频率和粪便形态均未改变。
对于所有患者,胃肠道症状总评分量表的中位数以及胃肠道症状评分量表消化不良和便秘子量表的中位数均显著降低,而腹胀减轻的视觉模拟评分中位数显著升高。SIBO组和非SIBO组这些症状的改善情况相同,表明DKT对小肠细菌没有影响。未报告严重副作用。
无论是否存在SIBO,DKT治疗均改善了慢性便秘患者的生活质量,且对小肠细菌无影响。UMIN临床试验注册标识符:UMIN000008070。